Risk factors for hospitalization and transfusion criteria in dengue patients
Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection: A Prospective Observational Study
This project will try to find which clinical signs and lab results predict whether people aged 5 and up with confirmed dengue will need hospitalization or a blood transfusion.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 5 Years and up |
| Sex | All |
| Sponsor | Clinica Mexico Academic / other |
| Locations | 1 site (Piedras Negras, Coahuila) |
| Trial ID | NCT07007585 on ClinicalTrials.gov |
What this trial studies
This is a 3-year prospective observational study at a second-level hospital in northern Mexico that will enroll consecutive patients with laboratory-confirmed dengue who first present to the emergency department or outpatient clinic. Investigators will collect clinical data (fever duration, bleeding signs, vomiting, abdominal pain) and laboratory results (platelet count, hematocrit) along with detailed transfusion records. Patients will be followed from initial presentation until clinical resolution or hospital discharge. Multivariate logistic regression will be used to identify independent predictors of hospitalization and transfusion and to describe real-world transfusion practices and outcomes in this setting.
Who should consider this trial
Good fit: People aged 5 years and older with laboratory-confirmed dengue who present first to the participating emergency department or outpatient clinic and can provide informed consent (or have a legal guardian provide consent) are ideal candidates.
Not a fit: Patients with co-infection (other arboviruses or COVID-19), pre-existing hematologic or oncologic disease, or those who refuse consent are excluded and unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, the findings could help clinicians in similar hospitals decide who needs admission or transfusion more accurately, potentially reducing unnecessary hospital stays and improving patient safety.
How similar studies have performed: Other observational studies have identified predictors of severe dengue, but transfusion criteria and practices remain variable and region-specific data are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥5 years * Laboratory-confirmed dengue infection (NS1, IgM, or PCR) * First contact at emergency or outpatient services * Informed consent signed by the patient or legal guardian Exclusion Criteria: * Co-infection with other arboviruses or COVID-19 * Pre-existing hematologic or oncologic disease * Refusal to sign informed consent
Where this trial is running
Piedras Negras, Coahuila
- Clinica Mexico — Piedras Negras, Coahuila, Mexico (Recruiting)
Study contacts
- Study coordinator: JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, MD, MSc, Ph, Specialist
- Email: jefe.urgencias@clinicamexico.com
- Phone: 525525848735
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.